This Investment is Ticking All the Boxes and Then Some: Arrowhead Pharmaceuticals, Inc.

investchronicle 18

Arrowhead Pharmaceuticals, Inc. kicked off the trading day on 08/22/19 with a price decrease of -6.90%, equivalent to -$2.38 relative change for the day. Taking a more long-term approach, ARWR had a 52-week range of $10.41 to $35.41. At the time of this article’s publishing, this stock is trading at $32.12 after starting the trading session at $34.60. Moving on, the stock has demonstrated a 52-week change amounting to 69.27, alongside an S&P500 52-Week Change of 58.73. At the time of writing, this stock’s 50-day Moving Average stands at $28.58, while the 200-day Moving Average of this stock is currently $20.01.

Currently, this company’s share volume is sitting at $1,787,197, but has maintained average daily volume of $1.89M. This stock has generated an average Year to Date volume of $1.74 million, alongside an average 20-day volume of $1.2 million. This publicly-traded company’s shares outstanding now amounts to $89.16 million, simultaneously with a float of $86.99 million. The organization now has a market capitalization sitting at $2.86 billion.

Arrowhead Pharmaceuticals, Inc.(ARWR) Ownership Data

Now let’s turn our focus to how large-scale investors are behaving with this stock. Arrowhead Pharmaceuticals, Inc.’s current insider ownership accounts for 3.70%, in contrast to 83.10% institutional ownership. According to the most recent latest insider trade that took place on Jun 26 this organization’s Director sold 17,756 at the rate of 27.61, making the entire transaction hit 490,243 in total value, affecting insider ownership by 1,900. Preceding that transaction, on May 31 Company’s Chief Financial Officer exercised an option 35,000 at a price of 4.94, making the whole transaction’s value amount to 172,800. This particular insider is now the holder of 313,536 in total.

If we take a glance at the Ownership summary of Arrowhead Pharmaceuticals, Inc.’s stock, 236 Institutional holders make up 80.12% of its total stock ownership. All together, they are the legal holders of 76,357,027 shares, which are valued at about $2,574,758,950 in total. If we focus on the top 3 stockholders for this publicly-traded organization, BLACKROCK INC. owns 14.84 million shares, with VANGUARD GROUP INC in 2nd place owning 8.64 million shares and OPPENHEIMERFUNDS, INC. in third place with total ownership of 7.8 million shares.

Arrowhead Pharmaceuticals, Inc. (ARWR) Earnings and Revenue Data

The corporation racked up revenue of $48.15million for the previous financial quarter, compared to the mean analyst estimate of $42.99 million. This company achieved a net margin of 33.28 while generating a return on equity of 28.53. Arrowhead Pharmaceuticals, Inc.’s full-quarter revenue increased by 5749.32%, when compared against the year-ago quarter. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.29 per share during the current fiscal year.

Arrowhead Pharmaceuticals, Inc.’s EPS decrease for this current 12-month fiscal period is -39.90%, and is forecasted to reach -124.70% in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by 7.33% through the next 5 years, which can be compared against the 12.90% growth it accomplished over the previous five years trading on the market.

Additional Trading Performance Indicators

Now turning our attention to the current performance indicators for Arrowhead Pharmaceuticals, Inc., this organization’s Quick Ratio in the last reported quarter now stands at 2.80. The company has managed to achieve an average true range (ATR) of 1.50. Alongside those, its PE Ratio stands at $70.28, and its Beta score is 1.53.

Another valuable indicator worth considering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 20.93 for this organization. Similarly, its price to free cash flow for trailing twelve months is now 18.89. Plus, this company’s price to book ratio for the last three-month fiscal period reported is 13.50, whereas its price to cash per share for the last quarter landed at 2.66.

In the same vein, ARWR’s Diluted EPS (Earnings per Share) trailing twelve months was posted at 0.46, a figure that is expected to reach 0.10 in the next reported quarter, and analysts expect it will be -124.70% at the market close of one year from today’s date.